The Life Sciences Report | TalkMarkets | Page 3

The Life Sciences Report

Experience, Creativity And Dedication To Finding And Presenting The Best Investment Ideas
Contributor's Links: The Life Sciences Report
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. The Streetwise Reports Team combines experience, creativity and dedication to ...more
Following: 17 Followers: 3026

All Contributions

Latest Posts
33 to 43 of 43 Posts
<<< 1 2 3
Sprott Fund Manager Jason Mayer's Guide To Resource Stock Profits
Tuesday, September 23, 2014 10:27 PM EDT
Sprott shares his criteria for selecting profitable investments in volatile resource markets, plus near- and long-term plays that look poised to deliver returns.
In this article: ABX, APC, BIREF, KGILF, MNDJF, OEXFF, SRTNF, TREVF, TRMLF, YGRAF
Read
Oil Field Services Surprise: The Upstart That Could Compete With The Big Three
Wednesday, September 10, 2014 8:55 PM EDT
Consolidation is coming to the oil and gas industry, says Brandon Dobell of William Blair & Co.
In this article: CJES, ENSV
Read
America's First Oil Sands Producer And Other Natural Resources Surprises
Wednesday, September 10, 2014 6:24 PM EDT
The natural resources space has been difficult in recent years. Potash prices collapsed, uranium spot prices hit a nine-year low, the gas market was in glut. Only oil has stayed strong.
In this article: ARW, BHP, NRT, RIO, UEC, URE, URZ, TSLA, AMSE
Read
Biotechs With Upside Possibilities Target Ebola And Liver Disease: MLV & Co.'s Vernon Bernardino
Wednesday, September 10, 2014 3:43 PM EDT
In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.
In this article: NBS, GALT, BCRX, SHPG, DVAX, ICPT, ABBV, CNAT, GLMD, IMNP
Read
Where To Stash Your Money When Europe Heats Up
Wednesday, September 10, 2014 3:18 PM EDT
In this Interview, Marin Katusa shares four junior names he thinks could profit from a move into modern energy production techniques, and one truly contrarian name for those expecting the worst.
In this article: PRD.TSXV, CCJ, UEC, VET
Read
Steve Brozak: Big-Picture Biotech Stocks Rule The Future
Friday, September 5, 2014 3:50 PM EDT
When Steve Brozak performs diligence on biotech stocks, he's always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow's healthcare system.
In this article: CAH, JNJ, MRK, PFE, NBS, CLDX, OMER, ATHX, CEMP
Read
Laidlaw's Yale Jen: Biotech 101 For Buyers And Sellers
Friday, August 29, 2014 5:36 AM EDT
Former biotech consultant Yale Jen picked up a few tricks advising companies on their pipelines before he came to Wall Street as a sellside analyst.
In this article: GSK, PFE, ISIS, RPRX, BIIB, MSTX, ADMA, GLYC
Read
Wedbush Securities' Liana Moussatos On The Art And Science Of Picking Biotechs With Upside
Thursday, August 21, 2014 3:17 PM EDT
Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike. She, like other successful investors, picks her targets and takes profits earlier, while less sophisticated investors wait for the press releases.
In this article: CPT, GALT, ALXN, OMER, PCRX, XOMA, UTHR
Read
Medtech Shifts From High Gear Into Overdrive: Canaccord’s William Plovanic
Wednesday, August 20, 2014 4:06 AM EDT
Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range.
In this article: JNJ, MDT, VRX, DXCM, ETRM, EXAC, NUVA, PODD, ELOS, ZLTQ
Read
Bring On The Orphans: Aegis Capital's Raghuram Selvaraju Lays Out A Winning Biotech Strategy
Thursday, August 14, 2014 6:48 AM EDT
For former drug researcher Raghuram "Ram" Selvaraju, picking biotech stocks is both science and art. It's about understanding the competitive landscape and the mechanisms of drug action, and then making sure all the pieces fit together for a plausible investment case.
In this article: AGN, AZN, GSK, JNJ, PFE, SNY, VRX, CUR, PLX, ACOR, ALXN, MDVN, SCLN, AUXL, ABBV
Read
Taking Stock Of The New Normal: Mark Landy On New Growth Ideas For Biotech Investors
Friday, August 8, 2014 6:06 PM EDT
Medical technology is intimately linked to regenerative medicine. You could say these industries have a thunder-and-lightning relationship.
In this article: JNJ, ANIK, HART
Read
33 to 43 of 43 Posts
<<< 1 2 3